Samantha C Burnham1, Pierrick Bourgeat2, Vincent Doré3, Greg Savage4, Belinda Brown5, Simon Laws6, Paul Maruff7, Olivier Salvado2, David Ames8, Ralph N Martins9, Colin L Masters10, Christopher C Rowe11, Victor L Villemagne12. 1. eHealth, CSIRO Health and Biosecurity, Floreat, WA, Australia. 2. eHealth, CSIRO Health and Biosecurity, Herston, QLD, Australia. 3. eHealth, CSIRO Health and Biosecurity, Herston, QLD, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia. 4. ARC Centre of Excellence in Cognition and its Disorders, Department of Psychology, Macquarie University, North Ryde, NSW, Australia. 5. Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia. 6. Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia; School of Biomedical Sciences, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia. 7. Cogstate, Melbourne, VIC, Australia. 8. Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia. 9. Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia. 10. Florey Institute, University of Melbourne, Parkville, VIC, Australia. 11. Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia. 12. Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia; Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia. Electronic address: victorlv@unimelb.edu.au.
Abstract
BACKGROUND: Brain amyloid β (Aβ) deposition and neurodegeneration have been documented in about 50-60% of cognitively healthy elderly individuals (aged 60 years or older). The long-term cognitive consequences of the presence of Alzheimer's disease pathology and neurodegeneration, and whether they have an independent or synergistic effect on cognition, are unclear. We aimed to characterise the long-term clinical and cognitive trajectories of healthy elderly individuals using a two-marker (Alzheimer's disease pathology and neurodegeneration) imaging construct. METHODS: Between Nov 3, 2006, and Nov 25, 2014, 573 cognitively healthy individuals in Melbourne and Perth, Australia, (mean age 73·1 years [SD 6·2]; 58% women) were enrolled in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by PET, and neurodegeneration (N) was established by measuring hippocampal volume using MRI. Individuals were categorised as A(-)N(-), A(+)N(-), A(+)N(+), or suspected non-Alzheimer's disease pathophysiology (A(-)N(+), SNAP). Clinical progression, hippocampal volume, standard neuropsychological tests, and domain-specific and global cognitive composite scores were assessed over 6 years of follow-up. Linear mixed effect models and a Cox proportional hazards model of survival were used to evaluate, compare, and contrast the clinical, cognitive, and volumetric trajectories of patients in the four AN categories. FINDINGS: 50 (9%) healthy individuals were classified as A(+)N(+), 87 (15%) as A(+)N(-), 310 (54%) as A(-)N(-), and 126 (22%) as SNAP. APOE ε4 was more frequent in participants in the A(+)N(+) (27; 54%) and A(+)N(-) (42; 48%) groups than in the A(-)N(-) (66; 21%) and SNAP groups (23; 18%). The A(+)N(-) and A(+)N(+) groups had significantly faster cognitive decline than the A(-)N(-) group (0·08 SD per year for AIBL-Preclinical AD Cognitive Composite [PACC]; p<0·0001; and 0·25; p<0·0001; respectively). The A (+)N(+) group also had faster hippocampal atrophy than the A(-)N(-) group (0·04 cm(3) per year; p=0·02). The SNAP group generally did not show significant decline over time compared with the A(-)N(-) group (0·03 SD per year [p=0·19] for AIBL-PACC and a 0·02 cm(3) per year increase [p=0·16] for hippocampal volume), although SNAP was sometimes associated with lower baseline cognitive scores (0·20 SD less than A(-)N(-) for AIBL-PACC). Within the follow-up, 24% (n=12) of individuals in the A(+)N(+) group and 16% (n=14) in the A(+)N(-) group progressed to amnestic mild cognitive impairment or Alzheimer's disease, compared with 9% (n=11) in the SNAP group. INTERPRETATION: Brain amyloidosis, a surrogate marker of Alzheimer's disease pathology, is a risk factor for cognitive decline and for progression from preclinical stages to symptomatic stages of the disease, with neurodegeneration acting as a compounding factor. However, neurodegeneration alone does not confer a significantly different risk of cognitive decline from that in the group with neither brain amyloidosis or neurodegeneration. FUNDING: CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF), National Health and Medical Research Council, the Dementia Collaborative Research Centres programme, McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria.
BACKGROUND: Brain amyloid β (Aβ) deposition and neurodegeneration have been documented in about 50-60% of cognitively healthy elderly individuals (aged 60 years or older). The long-term cognitive consequences of the presence of Alzheimer's disease pathology and neurodegeneration, and whether they have an independent or synergistic effect on cognition, are unclear. We aimed to characterise the long-term clinical and cognitive trajectories of healthy elderly individuals using a two-marker (Alzheimer's disease pathology and neurodegeneration) imaging construct. METHODS: Between Nov 3, 2006, and Nov 25, 2014, 573 cognitively healthy individuals in Melbourne and Perth, Australia, (mean age 73·1 years [SD 6·2]; 58% women) were enrolled in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by PET, and neurodegeneration (N) was established by measuring hippocampal volume using MRI. Individuals were categorised as A(-)N(-), A(+)N(-), A(+)N(+), or suspected non-Alzheimer's disease pathophysiology (A(-)N(+), SNAP). Clinical progression, hippocampal volume, standard neuropsychological tests, and domain-specific and global cognitive composite scores were assessed over 6 years of follow-up. Linear mixed effect models and a Cox proportional hazards model of survival were used to evaluate, compare, and contrast the clinical, cognitive, and volumetric trajectories of patients in the four AN categories. FINDINGS: 50 (9%) healthy individuals were classified as A(+)N(+), 87 (15%) as A(+)N(-), 310 (54%) as A(-)N(-), and 126 (22%) as SNAP. APOE ε4 was more frequent in participants in the A(+)N(+) (27; 54%) and A(+)N(-) (42; 48%) groups than in the A(-)N(-) (66; 21%) and SNAP groups (23; 18%). The A(+)N(-) and A(+)N(+) groups had significantly faster cognitive decline than the A(-)N(-) group (0·08 SD per year for AIBL-Preclinical AD Cognitive Composite [PACC]; p<0·0001; and 0·25; p<0·0001; respectively). The A (+)N(+) group also had faster hippocampal atrophy than the A(-)N(-) group (0·04 cm(3) per year; p=0·02). The SNAP group generally did not show significant decline over time compared with the A(-)N(-) group (0·03 SD per year [p=0·19] for AIBL-PACC and a 0·02 cm(3) per year increase [p=0·16] for hippocampal volume), although SNAP was sometimes associated with lower baseline cognitive scores (0·20 SD less than A(-)N(-) for AIBL-PACC). Within the follow-up, 24% (n=12) of individuals in the A(+)N(+) group and 16% (n=14) in the A(+)N(-) group progressed to amnestic mild cognitive impairment or Alzheimer's disease, compared with 9% (n=11) in the SNAP group. INTERPRETATION:Brain amyloidosis, a surrogate marker of Alzheimer's disease pathology, is a risk factor for cognitive decline and for progression from preclinical stages to symptomatic stages of the disease, with neurodegeneration acting as a compounding factor. However, neurodegeneration alone does not confer a significantly different risk of cognitive decline from that in the group with neither brain amyloidosis or neurodegeneration. FUNDING: CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF), National Health and Medical Research Council, the Dementia Collaborative Research Centres programme, McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria.
Authors: David S Knopman; Samantha Budd Haeberlein; Maria C Carrillo; James A Hendrix; Geoff Kerchner; Richard Margolin; Paul Maruff; David S Miller; Gary Tong; Maria B Tome; Melissa E Murray; Peter T Nelson; Mary Sano; Niklas Mattsson; David L Sultzer; Thomas J Montine; Clifford R Jack; Hartmuth Kolb; Ronald C Petersen; Prashanthi Vemuri; Megan Zoschg Canniere; Julie A Schneider; Susan M Resnick; Gary Romano; Argonde Corien van Harten; David A Wolk; Lisa J Bain; Eric Siemers Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Jennifer S Rabin; Aaron P Schultz; Trey Hedden; Anand Viswanathan; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Rachel F Buckley; Hyun-Sik Yang; Michael Properzi; Vaishnavi Rao; Dylan R Kirn; Kathryn V Papp; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Alberto J Espay; Joaquin A Vizcarra; Luca Marsili; Anthony E Lang; David K Simon; Aristide Merola; Keith A Josephs; Alfonso Fasano; Francesca Morgante; Rodolfo Savica; J Timothy Greenamyre; Franca Cambi; Tritia R Yamasaki; Caroline M Tanner; Ziv Gan-Or; Irene Litvan; Ignacio F Mata; Cyrus P Zabetian; Patrik Brundin; Hubert H Fernandez; David G Standaert; Marcelo A Kauffman; Michael A Schwarzschild; S Pablo Sardi; Todd Sherer; George Perry; James B Leverenz Journal: Neurology Date: 2019-02-12 Impact factor: 9.910
Authors: Rachel F Buckley; Elizabeth C Mormino; Rebecca E Amariglio; Michael J Properzi; Jennifer S Rabin; Yen Ying Lim; Kathryn V Papp; Heidi I L Jacobs; Samantha Burnham; Bernard J Hanseeuw; Vincent Doré; Annette Dobson; Colin L Masters; Michael Waller; Christopher C Rowe; Paul Maruff; Michael C Donohue; Dorene M Rentz; Dylan Kirn; Trey Hedden; Jasmeer Chhatwal; Aaron P Schultz; Keith A Johnson; Victor L Villemagne; Reisa A Sperling Journal: Alzheimers Dement Date: 2018-05-24 Impact factor: 21.566
Authors: Michael E Belloy; Valerio Napolioni; Summer S Han; Yann Le Guen; Michael D Greicius Journal: JAMA Neurol Date: 2020-07-01 Impact factor: 18.302
Authors: Murat Bilgel; Yang An; Jessica Helphrey; Wendy Elkins; Gabriela Gomez; Dean F Wong; Christos Davatzikos; Luigi Ferrucci; Susan M Resnick Journal: Brain Date: 2018-08-01 Impact factor: 13.501